Embecta Corp. (NASDAQ:EMBC - Get Free Report) was the target of a significant decline in short interest in November. As of November 30th, there was short interest totalling 1,220,000 shares, a decline of 5.4% from the November 15th total of 1,290,000 shares. Currently, 2.3% of the company's shares are short sold. Based on an average daily trading volume, of 388,100 shares, the days-to-cover ratio is presently 3.1 days.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. CWM LLC lifted its position in Embecta by 11.3% during the third quarter. CWM LLC now owns 10,102 shares of the company's stock valued at $142,000 after buying an additional 1,023 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Embecta by 4.8% during the second quarter. The Manufacturers Life Insurance Company now owns 22,212 shares of the company's stock valued at $278,000 after buying an additional 1,025 shares in the last quarter. SummerHaven Investment Management LLC lifted its position in Embecta by 3.4% during the second quarter. SummerHaven Investment Management LLC now owns 36,198 shares of the company's stock valued at $452,000 after buying an additional 1,179 shares in the last quarter. Ceera Investments LLC lifted its position in Embecta by 0.9% during the second quarter. Ceera Investments LLC now owns 178,353 shares of the company's stock valued at $2,229,000 after buying an additional 1,514 shares in the last quarter. Finally, Natixis Advisors LLC lifted its position in Embecta by 5.7% during the third quarter. Natixis Advisors LLC now owns 30,735 shares of the company's stock valued at $433,000 after buying an additional 1,648 shares in the last quarter. 93.83% of the stock is owned by institutional investors and hedge funds.
EMBC opened at $19.99 on Tuesday. The company's 50 day simple moving average is $15.96 and its 200 day simple moving average is $14.71. Embecta has a 1 year low of $9.93 and a 1 year high of $21.48. The stock has a market capitalization of $1.16 billion, a PE ratio of 14.81, a P/E/G ratio of 1.08 and a beta of 1.25.
Embecta (NASDAQ:EMBC - Get Free Report) last released its earnings results on Tuesday, November 26th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.05. Embecta had a net margin of 6.97% and a negative return on equity of 18.54%. The business had revenue of $286.10 million for the quarter, compared to analysts' expectations of $276.97 million. During the same period last year, the company earned $0.59 earnings per share. The company's quarterly revenue was up 1.5% on a year-over-year basis. As a group, sell-side analysts expect that Embecta will post 2.84 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 18th. Shareholders of record on Friday, December 6th will be given a dividend of $0.15 per share. The ex-dividend date is Friday, December 6th. This represents a $0.60 dividend on an annualized basis and a yield of 3.00%. Embecta's dividend payout ratio (DPR) is 44.44%.
EMBC has been the subject of a number of recent research reports. BTIG Research upgraded shares of Embecta from a "neutral" rating to a "buy" rating and set a $26.00 price target for the company in a report on Wednesday, November 27th. Morgan Stanley raised shares of Embecta from an "underweight" rating to an "equal weight" rating and raised their target price for the stock from $13.00 to $20.00 in a research report on Monday, December 2nd.
View Our Latest Stock Analysis on EMBC
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Embecta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Embecta wasn't on the list.
While Embecta currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.